Renal Replacement Therapy

• 

  Subject Areas on Research

  • AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. 
  • African American and non-African American patients' and families' decision making about renal replacement therapies. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. 
  • Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. 
  • COVID-19 and the Kidney Community: Coalescing in Crisis. 
  • Care of the undocumented immigrant in the United States with ESRD. 
  • Chronic kidney disease and stroke. 
  • Clinical Pharmacology Studies in Critically Ill Children. 
  • Comparative health services research across populations: the unused opportunities in big data. 
  • Comparison of life participation activities among adults treated by hemodialysis, peritoneal dialysis, and kidney transplantation: a systematic review. 
  • Development of a decision aid to inform patients' and families' renal replacement therapy selection decisions. 
  • Dialysis or transplantation: fitting the treatment to the patient. 
  • Discussions of the kidney disease trajectory by elderly patients and nephrologists: a qualitative study. 
  • Disparities in worldwide treatment of kidney failure. 
  • Effects of low-dose atrial natriuretic peptide infusion on cardiac surgery-associated acute kidney injury: A multicenter randomized controlled trial. 
  • External Validation for Acute Kidney Injury Severity Scores: A Multicenter Retrospective Study in 14 Japanese ICUs. 
  • Extracorporeal liver support for trauma-induced hepatic dysfunction. 
  • FGF-23 levels in patients with AKI and risk of adverse outcomes. 
  • Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. 
  • Factors predicting successful discontinuation of continuous renal replacement therapy. 
  • Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. 
  • Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19. 
  • Implementation of the Dialysis Outcomes Quality Initiative Vascular Access Guidelines. 
  • Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. 
  • Nutrients and micronutrients at risk during renal replacement therapy: a scoping review. 
  • Outcomes of Acute Kidney Injury in Patients With Severe ARDS Due to Influenza A(H1N1) pdm09 Virus. 
  • Patient Education and Support During CKD Transitions: When the Possible Becomes Probable. 
  • Perioperative Implications of End-stage Renal Disease in Orthopaedic Surgery. 
  • Protocolized Care for Early Septic Shock (ProCESS) statistical analysis plan. 
  • Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. 
  • Selecting renal replacement therapies: what do African American and non-African American patients and their families think others should know? A mixed methods study. 
  • Sepsis may not be a risk factor for mortality in patients with acute kidney injury treated with continuous renal replacement therapy. 
  • Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. 
  • Specialist and primary care physicians' views on barriers to adequate preparation of patients for renal replacement therapy: a qualitative study. 
  • The Acute Dialysis Orders Objective Structured Clinical Examination (OSCE): Fellow Performance on a Formative Assessment of Acute Kidney Replacement Therapy Competence. 
  • The Effects of Alternative Resuscitation Strategies on Acute Kidney Injury in Patients with Septic Shock. 
  • The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. 
  • The growing burden of chronic kidney disease in Pakistan. 
  • The lower limit of intensity to control uremia during continuous renal replacement therapy. 
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. 
  • Timing is everything? Reconciling the results of recent trials in acute kidney injury. 
  • Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. 
  • Who may not benefit from continuous renal replacement therapy in acute kidney injury? 
• 

  Keywords of People

  • Patel, Uptal Dinesh, Adjunct Professor in the Department of Medicine, Medicine, Nephrology